Cargando…

A single epidermal stem cell strategy for safe ex vivo gene therapy

There is a widespread agreement from patient and professional organisations alike that the safety of stem cell therapeutics is of paramount importance, particularly for ex vivo autologous gene therapy. Yet current technology makes it difficult to thoroughly evaluate the behaviour of genetically corr...

Descripción completa

Detalles Bibliográficos
Autores principales: Droz-Georget Lathion, Stéphanie, Rochat, Ariane, Knott, Graham, Recchia, Alessandra, Martinet, Danielle, Benmohammed, Sara, Grasset, Nicolas, Zaffalon, Andrea, Besuchet Schmutz, Nathalie, Savioz-Dayer, Emmanuelle, Beckmann, Jacques Samuel, Rougemont, Jacques, Mavilio, Fulvio, Barrandon, Yann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403041/
https://www.ncbi.nlm.nih.gov/pubmed/25724200
http://dx.doi.org/10.15252/emmm.201404353
_version_ 1782367305319055360
author Droz-Georget Lathion, Stéphanie
Rochat, Ariane
Knott, Graham
Recchia, Alessandra
Martinet, Danielle
Benmohammed, Sara
Grasset, Nicolas
Zaffalon, Andrea
Besuchet Schmutz, Nathalie
Savioz-Dayer, Emmanuelle
Beckmann, Jacques Samuel
Rougemont, Jacques
Mavilio, Fulvio
Barrandon, Yann
author_facet Droz-Georget Lathion, Stéphanie
Rochat, Ariane
Knott, Graham
Recchia, Alessandra
Martinet, Danielle
Benmohammed, Sara
Grasset, Nicolas
Zaffalon, Andrea
Besuchet Schmutz, Nathalie
Savioz-Dayer, Emmanuelle
Beckmann, Jacques Samuel
Rougemont, Jacques
Mavilio, Fulvio
Barrandon, Yann
author_sort Droz-Georget Lathion, Stéphanie
collection PubMed
description There is a widespread agreement from patient and professional organisations alike that the safety of stem cell therapeutics is of paramount importance, particularly for ex vivo autologous gene therapy. Yet current technology makes it difficult to thoroughly evaluate the behaviour of genetically corrected stem cells before they are transplanted. To address this, we have developed a strategy that permits transplantation of a clonal population of genetically corrected autologous stem cells that meet stringent selection criteria and the principle of precaution. As a proof of concept, we have stably transduced epidermal stem cells (holoclones) obtained from a patient suffering from recessive dystrophic epidermolysis bullosa. Holoclones were infected with self-inactivating retroviruses bearing a COL7A1 cDNA and cloned before the progeny of individual stem cells were characterised using a number of criteria. Clonal analysis revealed a great deal of heterogeneity among transduced stem cells in their capacity to produce functional type VII collagen (COLVII). Selected transduced stem cells transplanted onto immunodeficient mice regenerated a non-blistering epidermis for months and produced a functional COLVII. Safety was assessed by determining the sites of proviral integration, rearrangements and hit genes and by whole-genome sequencing. The progeny of the selected stem cells also had a diploid karyotype, was not tumorigenic and did not disseminate after long-term transplantation onto immunodeficient mice. In conclusion, a clonal strategy is a powerful and efficient means of by-passing the heterogeneity of a transduced stem cell population. It guarantees a safe and homogenous medicinal product, fulfilling the principle of precaution and the requirements of regulatory affairs. Furthermore, a clonal strategy makes it possible to envision exciting gene-editing technologies like zinc finger nucleases, TALENs and homologous recombination for next-generation gene therapy.
format Online
Article
Text
id pubmed-4403041
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-44030412015-04-23 A single epidermal stem cell strategy for safe ex vivo gene therapy Droz-Georget Lathion, Stéphanie Rochat, Ariane Knott, Graham Recchia, Alessandra Martinet, Danielle Benmohammed, Sara Grasset, Nicolas Zaffalon, Andrea Besuchet Schmutz, Nathalie Savioz-Dayer, Emmanuelle Beckmann, Jacques Samuel Rougemont, Jacques Mavilio, Fulvio Barrandon, Yann EMBO Mol Med Research Articles There is a widespread agreement from patient and professional organisations alike that the safety of stem cell therapeutics is of paramount importance, particularly for ex vivo autologous gene therapy. Yet current technology makes it difficult to thoroughly evaluate the behaviour of genetically corrected stem cells before they are transplanted. To address this, we have developed a strategy that permits transplantation of a clonal population of genetically corrected autologous stem cells that meet stringent selection criteria and the principle of precaution. As a proof of concept, we have stably transduced epidermal stem cells (holoclones) obtained from a patient suffering from recessive dystrophic epidermolysis bullosa. Holoclones were infected with self-inactivating retroviruses bearing a COL7A1 cDNA and cloned before the progeny of individual stem cells were characterised using a number of criteria. Clonal analysis revealed a great deal of heterogeneity among transduced stem cells in their capacity to produce functional type VII collagen (COLVII). Selected transduced stem cells transplanted onto immunodeficient mice regenerated a non-blistering epidermis for months and produced a functional COLVII. Safety was assessed by determining the sites of proviral integration, rearrangements and hit genes and by whole-genome sequencing. The progeny of the selected stem cells also had a diploid karyotype, was not tumorigenic and did not disseminate after long-term transplantation onto immunodeficient mice. In conclusion, a clonal strategy is a powerful and efficient means of by-passing the heterogeneity of a transduced stem cell population. It guarantees a safe and homogenous medicinal product, fulfilling the principle of precaution and the requirements of regulatory affairs. Furthermore, a clonal strategy makes it possible to envision exciting gene-editing technologies like zinc finger nucleases, TALENs and homologous recombination for next-generation gene therapy. BlackWell Publishing Ltd 2015-04 2015-02-27 /pmc/articles/PMC4403041/ /pubmed/25724200 http://dx.doi.org/10.15252/emmm.201404353 Text en © 2015 The Authors. Published under the terms of the CC BY 4.0 license http://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Droz-Georget Lathion, Stéphanie
Rochat, Ariane
Knott, Graham
Recchia, Alessandra
Martinet, Danielle
Benmohammed, Sara
Grasset, Nicolas
Zaffalon, Andrea
Besuchet Schmutz, Nathalie
Savioz-Dayer, Emmanuelle
Beckmann, Jacques Samuel
Rougemont, Jacques
Mavilio, Fulvio
Barrandon, Yann
A single epidermal stem cell strategy for safe ex vivo gene therapy
title A single epidermal stem cell strategy for safe ex vivo gene therapy
title_full A single epidermal stem cell strategy for safe ex vivo gene therapy
title_fullStr A single epidermal stem cell strategy for safe ex vivo gene therapy
title_full_unstemmed A single epidermal stem cell strategy for safe ex vivo gene therapy
title_short A single epidermal stem cell strategy for safe ex vivo gene therapy
title_sort single epidermal stem cell strategy for safe ex vivo gene therapy
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403041/
https://www.ncbi.nlm.nih.gov/pubmed/25724200
http://dx.doi.org/10.15252/emmm.201404353
work_keys_str_mv AT drozgeorgetlathionstephanie asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT rochatariane asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT knottgraham asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT recchiaalessandra asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT martinetdanielle asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT benmohammedsara asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT grassetnicolas asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT zaffalonandrea asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT besuchetschmutznathalie asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT saviozdayeremmanuelle asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT beckmannjacquessamuel asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT rougemontjacques asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT maviliofulvio asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT barrandonyann asingleepidermalstemcellstrategyforsafeexvivogenetherapy
AT drozgeorgetlathionstephanie singleepidermalstemcellstrategyforsafeexvivogenetherapy
AT rochatariane singleepidermalstemcellstrategyforsafeexvivogenetherapy
AT knottgraham singleepidermalstemcellstrategyforsafeexvivogenetherapy
AT recchiaalessandra singleepidermalstemcellstrategyforsafeexvivogenetherapy
AT martinetdanielle singleepidermalstemcellstrategyforsafeexvivogenetherapy
AT benmohammedsara singleepidermalstemcellstrategyforsafeexvivogenetherapy
AT grassetnicolas singleepidermalstemcellstrategyforsafeexvivogenetherapy
AT zaffalonandrea singleepidermalstemcellstrategyforsafeexvivogenetherapy
AT besuchetschmutznathalie singleepidermalstemcellstrategyforsafeexvivogenetherapy
AT saviozdayeremmanuelle singleepidermalstemcellstrategyforsafeexvivogenetherapy
AT beckmannjacquessamuel singleepidermalstemcellstrategyforsafeexvivogenetherapy
AT rougemontjacques singleepidermalstemcellstrategyforsafeexvivogenetherapy
AT maviliofulvio singleepidermalstemcellstrategyforsafeexvivogenetherapy
AT barrandonyann singleepidermalstemcellstrategyforsafeexvivogenetherapy